Mind Cure Health (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research for psychedelics, has announced that co-founder and CEO Kelsey Ramsden is featured on the latest episode of the Bell2Bell podcast. The Bell2Bell Podcast offers its listeners insightful interviews with executives of companies operating in fast-moving industries. During the episode, hosted by InvestorBrandNetwork’s Stuart Smith, Ramsden provided an overview of the company’s business model and also discussed the changing regulatory and social environments surrounding psychedelic-assisted therapy. She also talked about the company’s current focus: the development of a clinical-grade, evidence-backed, science-based, AI-driven tool to enable therapists to deploy psychedelics in their clinics; patients can also use the app to assist in their care. Ideally, the app will result in better outcomes, shorter patient timeframes in clinic and even approval and unlocking insurance payments for psychedelics. “We’re a life sciences company that has two primary focal points,” said Mind Cure Health co-founder and CEO Kelsey Ramsden in the interview. “One side is digital therapeutics focused on psychedelic therapy and the other is drug development, again focused on psychedelic molecules. When we developed our model and our strategy of go-to-market. . . what we looked at was regulation and the timing of regulatory change to ensure that we were developing horizons of revenue that were going to line up with changes at the government level unlocking some of these molecules. What that meant for us was investigating molecular research that would be the blue-sky horizon, so independent of when the typical generic MDMA or psilocybin gets approved, we’re in charge of the approval process, meaning we do the clinical research on the novel molecule to get it to market. That is drug development. So, that’s one side. The side that was earliest was our digital therapeutics platform. In simple terms, what that means is that the market is going to have a lot of newly trained therapists and a lot of individuals who are new to psychedelic practice.”
To hear the full interview, visit https://ibn.fm/Ff8bw
To view the full press release, visit https://ibn.fm/2naH9
About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit www.MindCure.com.
NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment